These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15752565)

  • 1. Immune response after adjuvant mucosal immunization of mice with inactivated influenza virus.
    Zanvit P; Havlícková M; Tácner J; Jirkovská M; Petrásková P; Novotná O; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2005 Mar; 97(2):251-9. PubMed ID: 15752565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunization of CD4+ T cell-deficient mice with an inactivated virus induces IgG and IgA responses in serum and mucosal secretions.
    Sha Z; Kang SM; Compans RW
    Virology; 2005 Jan; 331(2):387-95. PubMed ID: 15629781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken.
    Xiaowen Z; Qinghua Y; Xiaofei Z; Qian Y
    Vaccine; 2009 Sep; 27(41):5628-32. PubMed ID: 19647063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A.
    Zanvit P; Tichopád A; Havlíčková M; Novotná O; Jirkovská M; Kološtová K; Cechová D; Julák J; Sterzl I; Prokešová L
    Immunol Lett; 2010 Nov; 134(1):26-34. PubMed ID: 20709105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcutaneous immunization with inactivated influenza virus induces protective immune responses.
    Skountzou I; Quan FS; Jacob J; Compans RW; Kang SM
    Vaccine; 2006 Aug; 24(35-36):6110-9. PubMed ID: 16766095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice.
    Song SK; Moldoveanu Z; Nguyen HH; Kim EH; Choi KY; Kim JB; Mestecky J
    Vaccine; 2007 Aug; 25(34):6359-66. PubMed ID: 17640781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal inoculation of Lactobacillus expressing hCGbeta induces an anti-hCGbeta antibody response in mice of different strains.
    Yao XY; Yuan MM; Li DJ
    Methods; 2006 Feb; 38(2):124-32. PubMed ID: 16414267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice.
    Hauge S; Madhun AS; Cox RJ; Brokstad KA; Haaheim LR
    Scand J Immunol; 2007 Jan; 65(1):14-21. PubMed ID: 17212762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
    Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
    Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.